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Abstract
Background: The activities of Rac1 and Cdc42 are essential for HRas-induced transformation of rodent fibroblasts.
What is more, expression of constitutively activated mutants of Rac1 and/or Cdc42 is sufficient for their malignant
transformation. The role for these two Rho GTPases in HRas-mediated transformation of human fibroblasts has not
been studied. Here we evaluated the contribution of Rac1 and Cdc42 to maintaining HRas-induced transformation
of human fibroblasts, and determined the ability of constitutively activated mutants of Rac1 or Cdc42 to induce
malignant transformation of a human fibroblast cell strain.
Methods: Under the control of a tetracycline regulatable promoter, dominant negative mutants of Rac1 and
Cdc42 were expressed in a human HRas-transformed, tumor derived fibroblast cell line. These cells were used to
determine the roles of Rac1 and/or Cdc42 proteins in maintaining HRas-induced transformed phenotypes. Similarly,
constitutively active mutants were expressed in a non-transformed human fibroblast cell strain to evaluate their
potential to induce malignant transformation. Affymetrix GeneChip arrays were used for transcriptome analyses,
and observed expression differences were subsequently validated using protein assays.
Results: Expression of dominant negative Rac1 and/or Cdc42 significantly altered transformed phenotypes of HRas
malignantly transformed human fibroblasts. In contrast, expression of constitutively active mutants of Rac1 or
Cdc42 was not sufficient to induce malignant transformation. Microarray analysis revealed that the expression of 29
genes was dependent on Rac1 and Cdc42, many of which are known to play a role in cancer. The dependence of
two such genes, uPA and VEGF was further validated in both normoxic and hypoxic conditions.
Conclusion(s): The results presented here indicate that expression of both Rac1 and Cdc42 is necessary for
maintaining several transformed phenotypes in oncogenic HRas transformed human cells, including their ability to
form tumors in athymic mice. Our data also indicate that expression of either activated Rac1 or Cdc42 alone is not
sufficient for malignant transformation of human fibroblasts, although each is required for specific transformed
phenotypes. Furthermore, our study elucidates that the expression of several highly significant cancer related genes
require the activities of Rac1 and/or Cdc42 which may also play a critical role in cellular transformation.
Background
The Ras-family of guanosine triphosphatases (GTPases)
regulates multiple cell processes, including cellular pro-
liferation, differentiation, and actin-cytoskeletal organi-
zation. Altered expression or activation of Ras
oncogenes has been found in ~30% of human cancers
[1,2]. Acting as a molecular switch, Ras cycles between
an inactive GDP-bound state and an active GTP-bound
conformation. In its active form, Ras initiates mitogenic
signals through various pathways, including the well-stu-
died Raf-MEK-ERK1/2, PI3K/Akt, and RalGDS cascades
(reviewed in [3]).
Two members of the Ras superfamily of small
GTPases, namely Rac1 and Cdc42, were first investi-
gated in Swiss-3T3 mouse fibroblasts and found to be
regulators of the actin cytoskeleton [4-6]. In these
reports, it was shown that Rac1 controlled lamellipodia
and ruffling behavior, whereas Cdc42 affected the
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keletal regulators, these small GTPases contribute to the
regulation of several signal transduction proteins,
including p21-activated kinase (PAK), p38/stress-acti-
vated protein kinases (SAPK), c-jun N-terminal kinases
(JNK), nuclear factor B( N F B), and serum-responsive
factor (SRF) [7].
The activities of Rac1 and Cdc42 are required for
transformation of NIH3T3 mouse fibroblasts and Rat1
fibroblasts by expression of oncogenic Ras [8,9]. In most
studies, constitutively-active (V12) mutants, or domi-
nant-negative (N17) mutants of Rac1 and/or Cdc42
have been used to elucidate the respective unique roles
each protein plays in oncogene transformation. For
example, in NIH3T3 mouse fibroblasts, as well as Rat1
fibroblasts, Rac1
V12 expression confers growth factor
independence, whereas Cdc42
V12 expression confers
anchorage independent growth [8]. However, in Swiss-
3T3 mouse fibroblasts, expression of either constitu-
tively active protein results in growth factor independent
proliferation [10]. This indicates that Rac1 and Cdc42
may have distinct roles in transformation depending on
the cell line and/or species from which the cells are
derived. However, in all three rodent fibroblast cell lines
previously evaluated, it has been shown that expression
of activated Rac1 or Cdc42 potentiated the ability for
these cells to form sarcomas following their subcuta-
neous injection into athymic mice [8-10]. Although it is
clear that Rac1 and Cdc42 play a role in HRas
V12-
induced transformation of rodent fibroblasts, HRas
V12-
induced transformation of human fibroblasts has been
considered to be mechanistically distinct [11].
The present study was designed to determine whether
the activity of Rac1, or Cdc42, or both, is required for
HRas
V12-induced transformation of human fibroblasts.
Moreover, we sought to identify Rac1-mediated and/or
Cdc42-mediated gene expression differences in the con-
text of oncogenic HRas signalling. Our data confirm
that activation of both Rac1 and Cdc42 is required for
such HRas
V12-induced transformation. In addition, using
a genomic array approach, we identified 29 genes whose
expression in HRas
V12-transformed cells is regulated by
Rac1 and/or Cdc42. Many of these genes, e.g. vascular
endothelial growth factor (VEGF) and urokinase plasmi-
nogen activator (uPA), have been shown to play a signif-
icant role in cancer.
Methods
Cell strains and culture conditions
Unless otherwise indicated, the growth medium for the
human foreskin-derived fibroblasts, i.e. MSU-1.1 and
PH3MT strains and their derivatives, was Eagle’s mini-
mal essential medium supplemented with 0.2 mM L-
aspartic acid, 0.2 mM L-serine, 1.0 mM sodium
pyruvate, and 10% supplemented calf serum (SCS)
(Hyclone Laboratories, Logan, UT). Penicillin, 100 units/
ml, and streptomycin, 100 μg/ml were also included. All
cell lines were cultured at 37°C in a humidified incuba-
tor containing 5% CO2, 95% ambient air.
To determine the genetic changes required for malig-
nant transformation of human fibroblasts, McCormick,
Maher, and their colleagues developed the MSU-1 line-
age of human fibroblasts, beginning with finite life span
skin fibroblasts derived from the foreskin of a normal
neonate [12]. The parental cell strain in that lineage
(designated MSU-1.1) is a chromosomally-stable, near-
diploid, telomerase-positive, infinite life span cell strain
that has been shown to be capable of being transformed
into malignant cells by transfection of numerous onco-
genes including HRas, NRas and KRas [13-17]. For
example, MSU-1.1 cells transfected with an over-
expressed oncogenic T24 HRas protein containing an
activating V12 mutation (HRas
V12)f o r m e ds a r c o m a s
when injected subcutaneously into athymic mice [15].
The malignant cell line, designated PH3MT, derived
from such a tumor was used in the present study.
Construction of human cell strains expressing dominant-
negative mutant genes under the control of tetracycline
The pTet-tTAk and pTet-splice vectors were purchased
from Invitrogen (Carlsbad, CA). This Tet-off system
allows tetracycline-regulated expression of genes in
mammalian cells. To facilitate selection, a pTet-tTAk
vector expressing a gene coding for histidinol resistance
was constructed and designated pTet-tTak
HisR.Ap T e t -
splice vector containing a gene coding for puromycin
resistance was also constructed and designated pTet-
PuroR. We derived the Flag-Cdc42
N17 and myc-Rac1
N17
mutant cDNAs by PCR amplification using PFU poly-
merase (Stratagene, La Jolla, CA), and separately sub-
cloned each into the pTet
PuroR vector. The cDNA
templates used for PCR amplification of Cdc42
N17 and
Rac1
N17 were kindly provided respectively by Dr. K.
Gallo (Michigan State University) and Dr. G. Bokoch
(Scripps Institute, La Jolla, CA). We verified the integrity
of the resulting pTet-Flag-Cdc42
N17 and pTet-myc-
Rac1
N17 vector constructs by automated DNA sequen-
cing (Visible Genetics, Bayer, Toronto, ON, Canada).
Lipofectamine (Invitrogen, Carlsbad, CA) was used to
transfect the plasmids into human cells per manufac-
turers protocol.
PH3MT cells were transfected with the pTet-tTak
HisR
vector, selected using histidinol (1 mM) (Sigma, St.
Louis, MO), and designated PH3MT-tTak-C1. Such
cells were subsequently transfected with the empty vec-
tor pTet
PuroR,o rw i t ht h ep T e t
PuroR vector containing
myc-Rac1
N17 cDNA, or with the pTet
PuroR vector con-
taining FLAG-Cdc42
N17 cDNA, and selected for resis-
tance to puromycin (0.5 μg/ml) (Sigma, St. Louis, MO).
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of the empty pTet-tTAk vector was also prepared and
was designated PH3MT-VC-C2. Two independent
clones that exhibited tetracycline-regulated expression of
myc-Rac1
N17 were chosen for study and designated
PH3MT-Rac1
N17 (-C1 or -C2). Two independent clones
with regulatable FLAG-Cdc42
N17 expression were simi-
larly selected and designated PH3MT-Cdc42
N17 (-C1,
and C2). A sixth cell strain, designated PH3MT-
Rac1
N17/Cdc42
N17, expressing both myc-Rac1
N17 and
FLAG-Cdc42
N17 dominant-negative proteins was also
isolated.
Construction of cell strains expressing constitutively-
activated mutants
To generate MSU-1.1 cell strains expressing GFP-
Rac1
V12 or GFP-Cdc42
V12 fusion proteins, the GFP
nucleotide sequence from the pCRUZ-GFP vector
(Santa Cruz Biotechnology, Santa Cruz, CA) was iso-
lated and ligated into the pcDNA6-V5-HisA vector
(Invitrogen, Carlsbad, CA), which confers blasticidin
resistance. Rac1
V12 and Cdc42
V12 cDNA template
sequences were purchased from University of Missouri-
Rolla Research Center (UMR) (Rolla, MO), PCR-ampli-
fied, and ligated downstream of the GFP nucleotide
sequence to enable the transfectants to express N-term-
inally-labelled proteins. The resulting constructs were
transfected into the parental, non-transformed MSU-1.1
cell strain, and selected for resistance to blasticidin (1
μg/ml) (Invitrogen, Carlsbad, CA) and screened for
expression of the GFP-fusion protein by fluorescence
microscopy. Identified clones were isolated, expanded,
and screened by Western blotting for GFP-tagged
Rac1
V12 or Cdc42
V12 protein expression.
Cell lysates and Western blot analysis
Whole cell protein extracts were prepared using a lysis
buffer consisting of 50 mM Tris-HCl, pH 7.2, 150 mM
N a C l ,5 0m MN a F ,0 . 5 %N P - 4 0 ,1m MN a 3V04,2 0 0
mM benzamidine, 1 mM PMSF, 25 μg/ml aprotinin,
and 25 μg/ml leupeptin. Total protein concentration
was quantified using the Coomassie protein assay
reagent (Pierce Biotechnolog y ,R o c k f o r d ,I L ) .L y s a t e s
were denatured in 5× Laemelli sample buffer, separated
by either 10% or 12% SDS-PAGE, and transferred to
PVDF membrane. The membrane was blocked for 2 hr
with Tris-buffered saline containing 0.1% Tween-20
(TBST) and 5% (w/v) non-fat milk. For the majority of
the studies, the membrane was probed overnight with
the primary antibody at 4°C, then probed for 1 hr at
room temperature with the appropriate horseradish per-
oxidase-linked secondary antibody (Sigma and Santa
Cruz Biotechnology). Both antibodies were diluted in
TBST containing 5% milk. The membrane was incu-
bated with the Supersignal West Pico chemiluminescent
horseradish peroxidase substrate (Pierce Biotechnology,
Rockford, IL) and then exposed to film. The primary
antibodies used were anti-FLAG, 1:1000 dilution (Sigma,
St. Louis, MO), anti-myc 9E10, 1:500 dilution, and anti-
GFP, 1:1000 dilution (Santa Cruz Biotechnology, Santa
Cruz, CA).
Focus reconstruction assay
The focus reconstruction assay was performed essen-
tially as described [15]. Briefly, MSU-1.1 cells were pla-
t e da tad e n s i t yo f5×1 0
4 cells per 100-mm diameter
dish containing growth medium supplemented with
0.5% SCS and 20 mM HEPES (pH 7.4) in the presence
or absence of tetracycline. On the following day, the
cells to be assayed for focus reconstruction were plated
(100-200 cells per dish) in these same dishes. Cells
received fresh medium every fourth day. After 3 weeks
of growth, the cells were fixed with neutral buffered for-
malin, stained with methylene blue, and then examined
for quality and quantity of foci.
Assay for growth factor independence
Cells were plated in growth medium containing 10%
SCS into a series of 60-mm diameter dishes at a density
of 10
4 cells per dish and incubated for 48 hr. The cells
were then washed twice and growth medium containing
0.5% SCS was added. The number of cells in three repli-
cate dishes was counted at the indicated intervals using
a Coulter counter. An equation derived from a best-fit
exponential curve was used to determine the doubling
time of cells in log-phase growth. This experiment was
repeated three times.
Assay for anchorage-independence
Cells were suspended in 0.33% top agarose, then plated
into 60-mm-diameter culture dishes at a 5 × 10
3 cells
per dish, and then covered with 2 mL of growth med-
ium. The growth medium was replaced weekly. After
three weeks, the cells were fixed with 2.5% glutaralde-
hyde. This experiment was repeated three times.
Assay for tumorigenicity
To test PH3MT derived cell strains, 10
6 cells were
injected subcutaneously into the right and left flank of a
series of athymic Balb/c mice. To turn off the domi-
nant-negative form of the proteins, tetracycline was
added to the drinking water of half of the mice, at a
concentration of 1 mg/ml. To mask the flavor of tetra-
cycline, 5% sucrose was added to the drinking water of
all mice. Tumor measurements were made weekly, and
mice were sacrificed when a tumor with a volume of 0.5
cm
3 developed on either flank. The tumorigenicity
results were displayed in the form of Kaplan-Meier sur-
vival plots using MedCalc Version 8.2 http://www.med-
calc.be. A log-rank test was used to determine statistical
significance.
To determine whether the MSU-1.1 derivative cell
strains expressing GFP-Rac
V12 or GFP-Cdc42
V12 were
capable of forming tumors in athymic mice, a 1 cm
3
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was placed in each flank. One week later, 10
7 cells were
injected directly into the sponges at each injection site.
Such sponges were used to ensure that a high number
of injected cells were retained at each injection site.
Affymetrix GeneChip expression analysis
PolyA+RNA was extracted using the Micropure PolyA
+RNA extraction kit according to the manufacturer’s
instructions (Ambion, Applied Biosystems, Austin, TX).
To synthesize cRNA products from 3 μgo fp o l y A
+RNA, the procedures described in the Affymetrix
expression analysis technical manual were followed. Per-
sonnel at the Genomics Technology Sequence Facility at
Michigan State University carried out the hybridization
to the Affymetrix HU95A human genome chip and
probed, washed, and scanned the arrays as described in
the Affymetrix manual. Such analysis was carried out in
duplicate.
Total mRNA expression was calculated for each gene
represented on the Affymetrix chip. Expression differ-
ences were calculated within each experiment as well as
between experiments. This approach resulted in four
separate data sets, i.e. both data sets collected from cells
grown in the presence of tetracycline were compared to
both data sets collected from cells grown in the absence
of tetracycline. To ascertain differentially expressed
genes, one-way parametric analysis of variance
(ANOVA) tests were performed by using a Benjamini-
Hochberg false discovery rate (BH FDR) for multiple
testing correction, with a P v a l u eo f0 . 0 5u s i n gM A S 5 . 0
software. The significant changes in each of the four
comparisons, as determined by the MAS5.0 software,
were identified using Microsoft Access query tool.
ELISA analyses
To detect levels of secreted uPA or VEGF protein from
PH3MT derived cells, cells were plated in 100 mm-dia-
meter culture dishes in growth medium containing tet-
racycline (1 mg/ml). After 24 hr, the medium was
removed, the cells were washed twice, and tetracycline-
free medium was added. Cells were incubated for
another 24 hr to allow for expression of dominant-nega-
tive genes. The cells were then washed twice, and given
medium lacking serum. After 24 hr the cells were sti-
mulated with growth medium, cobalt chloride (CoCl2)
(100 μM), deferoxamine (DFO) (100 μM) or were incu-
bated in a hypoxic chamber (1% O2) for 24 hr. To deter-
mine the level of secreted VEGF and uPA protein from
MSU-1.1 derivative cell strains, 1.5 × 10
5 cells were pla-
ted in a 100 mm-diameter tissue culture dish containing
growth medium, and incubated for 24 hr. The cells
were then washed twice with serum-free medium, and
serum-starved for another 24 hr before being stimulated
with growth medium containing 10% SCS. The media
were collected, and centrifuged at 5000 × g for 5 min.
To detect secreted VEGF protein, we carried out a sand-
wich ELISA using the human VEGF DuoSet (R&D Sys-
tems, Minneapolis, MN) ELISA kit following the
manufacturer’s protocol. To detect secreted levels of
uPA protein, a similar sandwich ELISA was carried out
using the uPA ELISA kit (Oncogene Science, Bayer,
Cambridge, MA) according to the manufacturer’s
protocol.
For all ELISA analyses, after the removal of condi-
tioned medium, whole cell protein extracts were made,
quantified, and used to normalize the levels of uPA and
VEGF protein detected by dividing the concentration of
uPA or VEGF protein in the conditioned medium by
the total amount of protein in the whole cell extract,
expressed as percent of vector control, or as fold-
change. Such experiments were repeated three times.
Error bars indicate the standard deviation from the
mean. To determine statistical significance, the student’s
two-tailed t-test was used.
Results
Role of Rac1 and Cdc42 proteins in HRasV12-
transformation of human fibroblasts
To investigate whether the activity of Rac1, Cdc42, or
both proteins, is required for HRas
V12-induced malig-
nant transformation of human fibroblasts, we trans-
fected PH3MT cells, a cell line that had been
malignantly-transformed by transfection of HRas
V12,
with plasmids encoding dominant negative forms of
Rac1 (Rac1
N17) and/or Cdc42 (Cdc42
N17). It is possible
that over-expression of these dominant negative proteins
may alter other signalling pathways by sequestering
exchange factors that are utilized by other members of
the Rho GTPase family in addition to Rac1 and/or
Cdc42. However, our use of these mutants allows for a
direct comparison of studies completed in human fibro-
blasts presented here to those studies completed in
rodent fibroblasts that used identical dominant-negative
or constitutively-active mutants. In these cells, expres-
sion of dominant negative mutants is controlled in a
Tet-off system, i.e., absence of tetracycline results in
dominant negative protein expression. Regulated expres-
sion of dominant negative mutant proteins was observed
in two independent clones of PH3MT cells transfected
with plasmids containing either Rac1
N17 or Cdc42
N17
(Fig. 1a). Regulated expression of both Rac1
N17 and
Cdc42
N17 was observed in one clone (Rac1
N17/
Cdc42
N17). As expected, dominant negative mutant
expression was not observed in parental cell strains
PH3MT-tTak-C1 or a vector control transfected cell
strain (PH3MT-VC-C2).
To evaluate the effect of dominant negative protein
expression on the transformed phenotype of PH3MT
cells, commonly used transformation assays including:
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Page 4 of 15Figure 1 A role for Rac1 and Cdc42 in focus reconstruction. (a) Cells were grown in the presence or absence of tetracycline (1 μg/ml).
PH3MT-tTak-C1 is the parental cell strain. PH3MT-VC-C2 is transfected with empty vector. Whole cell extracts were made and the Western blot
was probed with both myc and FLAG antibodies. b-actin levels were used to indicate loading. (b) Cells expressing dominant negative mutants
were plated on a lawn of non-transformed MSU-1.1 cells, and focus reconstruction was analyzed. Pictures are representative of replicate
experiments.
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struction, and tumor forming ability, were carried out.
Growth curve analysis revealed a significant increase in
the doubling time in all dominant negative protein
expressing clones cultured in medium lacking tetracy-
cline (dominant negative protein expression) relative to
their growth in medium containing tetracycline (domi-
nant negative protein expression suppressed) (p < 0.05)
(Table 1). A moderate increase in the doubling time of
the vector control in the absence of tetracycline was
also observed indicating some toxicity of tTak expres-
sion (p < 0.05). However, the extent to which tTak
expression alone affected doubling time was significantly
less than what was observed in all cell strains expressing
dominant negative proteins (p < 0.01). Focus reconstruc-
tion assays also revealed a significant decrease in the
ability of dominant negative protein expressing clones to
form foci on a lawn of non-transformed human fibro-
blasts (MSU-1.1 cells) (Fig. 1b). In general, expression of
Rac1
N17 affected both growth in reduced serum, and
focus reconstruction properties to a greater extent than
did expression of Cdc42
N17. These results suggest that
dominant negative protein expression does indeed affect
the transformed properties of PH3MT cells, and suggest
that the activities of both Rac1 and Cdc42 play a signifi-
cant role in the ability of HRas
V12-transformed cells to
grow in reduced serum conditions and to avoid contact
inhibition.
To determine whether the activities of Rac1 and/or
Cdc42 proteins are required for maintaining the ability
of PH3MT cells to form tumors in athymic mice, cells
expressing Rac1
N17,C d c 4 2
N17, or both mutant proteins,
were injected subcutaneously into athymic mice and
tumor growth was monitored. As a control, another set
of mice was injected with the parental cell strain,
PH3MT-tTAk-C1, or with vector control cell strain
PH3MT-VC-C2. By 15 weeks, all mice that had been
injected with the latter two cell strains, in the presence
or absence of tetracycline, developed tumors and were
sacrificed (Fig. 2a &2b). In contrast, dominant-negative
interference with Rac1 activity resulted in decreased
tumor-forming ability, and mice injected with these cells
showed a significant prolongation of a tumor-free life-
span (p < 0.01) (Fig. 2c &2d). However, not all mice
escaped tumor formation. We hypothesized that follow-
ing injection, cells with levels of dominant negative pro-
tein expression sufficient to prevent tumor growth were
selected against, while cells with low levels of mutant
protein expression were able to proliferate and resulted
in tumor formation. To examine this possibility, we
derived cell lines from resected tumors, selected for
injected cells using the puromycin resistance marker,
and compared the level of Rac1
N17 expression relative to
the level expressed in the cell strain prior to injection.
We were unable to detect Rac1
N17 in cell strains derived
from these tumors (Fig. 2e &2f). These results strongly
suggest that Rac1 activity plays a critical role in the abil-
ity of the transformed fibroblasts to form sarcomas, and
that when the dominant-negative protein expression is
suppressed, these cells re-acquire the ability to form
such tumors. Although there was no significant differ-
ence in the length of survival of mice injected with cells
expressing Cdc42
N17, subsequent Western blotting of
tumor-derived cell strains revealed similar results, i.e.,
these cell strains had lost detectable levels of expression
of dominant-negative proteins (Fig. 3a-d).
Subcutaneous injection of PH3MT cells expressing
both Rac1
N17 and Cdc42
N17 proteins resulted in signifi-
cantly prolonged tumor-free survival (p < 0.0001) (Fig.
3e). Again, not all mice escaped tumor formation.
Expression analysis of two tumor-derived cell lines
revealed undetectable levels of dominant-negative pro-
tein expression (Fig. 3f). These data suggest that the
activity of both Rac1 and Cdc42 is essential for
HRas
V12-induced transformation of human fibroblasts.
Role of Rac1
V12 or Cdc42
V12 protein in the transformation
of human fibroblasts
To further address the roles of Rac1 and Cdc42 in the
development of a transformed phenotype, we also evalu-
ated the ability of cells expressing activated mutants to
display transformed properties. Based on studies in
rodent fibroblasts, we hypothesized that expression of
Rac1
V12 or Cdc42
V12 in human fibroblasts would elicit a
transformed phenotype [8,9]. To test this hypothesis, we
stably transfected the parental MSU-1.1 cell strain with
vectors encoding GFP-Rac1
V12 or GFP-Cdc42
V12 pro-
teins (Fig. 4a), and assayed them for the ability to grow
in medium with reduced serum, form large colonies in
agarose, and develop into sarcomas in athymic mice.
Expression of Rac1
V12,b u tn o tC d c 4 2
V12 resulted in an
increased ability of MSU-1.1 fibroblasts to grow in med-
ium with reduced serum (Fig. 4b). Logarithmic extrapo-
lation revealed a doubling time of 19 hr in HRas
V12
Table 1 Growth Curve Analysis (doubling time in hrs)
Cell Line (+) Tet - GENE OFF (-) Tet - GENE ON
MSU-1.1 30.2 (± 1.0) 29.8 (± 0.7)
PH3 MT 19.9 (± 0.5) 19.4 (± 0.7)
Vector Control 16.6 (± 0.5) 20.4 (± 1.2)*
Cdc42
N17-C1 17.5 (± 2.0) 28.1 (± 2.0)**
Cdc42
N17-C2 17.0 (± 1.7) 26.6 (± 1.2)**
Rac1
N17-C1 16.3 (± 0.2) 31.2 (± 3.0)*
Rac1
N17-C2 16.6 (± 0.7) 31.4 (± 1.0)**
Rac1
N17/Cdc42
N17 18.2 (± 0.5) 35.8 (± 1.2)*
Values represent Mean ± SD
*,** represent a significant difference compared to (-) Tet condition using a
homoscedastic
two-tailed t-test (p < 0.05, p < 0.01, respectively), N = 3 for all conditions
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expressing Rac1
V12. This is in contrast to parental, vec-
tor-control, and Cdc42
V12 expressing cells which dis-
played doubling times of >30 hr.
The ability of cells to grow in reduced serum condi-
tions typically correlates with the potential to form
anchorage independent colonies in soft agar. To explore
this possibility, these same cell strains were suspended
in agarose and monitored for colony formation (Fig. 4c).
We found that expression of Cdc42
V12 confers the abil-
ity for these cells to form large anchorage independent
colonies, whereas expression of Rac1
V12 resulted in
inconsistent small colony formation. Together, these
data support the results of previous studies in mouse
and rat fibroblasts indicating a role for Rac1 in prolifera-
tion in reduced serum conditions and Cdc42 in ancho-
rage independent growth [8].
To determine whether Rac1
V12 or Cdc42
V12 expres-
sion in human fibroblasts results in malignant transfor-
mation, we subcutaneously injected these mutant
expressing cell strains into the flanks of athymic mice.
Surprisingly, neither Rac1
V12 nor Cdc42
V12 expression
Figure 2 Evidence that Rac1 activity is essential to maintain HRas
V12-induced tumor formation. Solid lines represent mice that were not
administered tetracycline (Tet). Dotted lines represent mice injected with the same cell strain, but mice were given Tet in order to suppress
dominant-negative expression. Tumors were measured weekly. When tumors reached a volume of approximately 0.5 cm
3, mice were sacrificed
and the tumors were removed for further analysis. The data are plotted using Kaplan-Meier analyses. (a) PH3MT-tTak-C1 (parent); N = 4 (- Tet), N
= 4 (+ Tet) p > 0.1. (b) PH3MT-VC-C2 (vector control); N = 5 (- Tet), N = 6 (+ Tet) p > 0.1. (c) PH3MT-Rac1
N17-C1; N = 7 (- Tet), N = 9 (+ Tet), p <
0.001. (d) PH3MT-Rac1
N17-C2; N = 4 (- Tet), N = 6 (+ Tet), p > 0.1. (e & f) Western blots probed with myc (9E10) antibody to detect dominant-
negative protein expression in two tumor-derived cell lines (Tumor 1 and Tumor 2) Both blots were probed with b-actin to verify loading.
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Page 7 of 15Figure 3 Evidence that Rac1 and/or Cdc42 activity is essential to maintain HRas
V12-induced tumor formation. Solid lines represent mice
that were not administered tetracycline (Tet). Dotted lines represent mice injected with the same cell strain, but mice were given Tet in order to
suppress dominant-negative expression. Tumors were measured weekly. When tumors reached a volume of approximately 0.5 cm
3, mice were
sacrificed and the tumors were removed for study. The data are plotted using Kaplan-Meier analyses. (a) PH3MT-Cdc42
N17-C1; N = 8 (- Tet), N =
8 (+ Tet), p > 0.1. (b) PH3MT-Cdc42
N17-C2; N = 6 (- Tet), N = 6 (+ Tet), p > 0.1. (c & d) Western blots probed with FLAG antibody to detect
dominant-negative protein expression in two tumor derived cell lines (Tumor 1 and Tumor 2). (e) PH3MT-Rac1
N17/Cdc42
N17; N = 9 (- Tet), N = 9
(+ Tet) p < 0.001. (f) Western blots probed with either myc (9E10) or FLAG antibody to detect dominant-negative protein expression in two
tumor derived cell lines (Tumor 1 and Tumor 2). All blots were probed with b-actin to verify loading.
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Page 8 of 15resulted in the ability for these cells to form tumors 28
weeks post injection (data not shown).
Identification of Rac1 and Cdc42 regulated genes in
HRas
V12-transformed human fibroblasts
Because the activities of both Rac1 and Cdc42 play
essential roles in mediating HRas
V12-induced transfor-
mation, we hypothesized that downstream effectors of
these two G-proteins play similarly indispensable roles.
To identify these genes, mRNA was harvested from the
PH3MT-Rac1
N17/Cdc42
N17 cell strain grown either in
the presence, or absence of tetracycline. Therefore, in
this analysis, the same cell strain was used as both the
control, i.e. normal Rac1 and Cdc42 signalling, and the
experimental, i.e. inhibited Rac1 and Cdc42 signalling,
groups. Using Affymetrix GeneChip technology, a total
of 29 significant expression differences were identified
(Table 2). The relatively small number and magnitude
of significant gene changes identified in this analysis is
likely attributable to the unique ability to compare tran-
scriptome differences in the same cell line, thereby
removing background “noise” typically observed in array
analyses comparing transcriptome profiles in indepen-
dent cell clones. Our criteria for choosing genes for fol-
low-up experiments included those genes that: 1) were
known to be affected by HRas mutations, and 2) had a
known role in cancer. Two such genes, uPA (urokinase
plasminogen activator) and VEGF (vascular endothelial
growth factor) were of particular interest since previous
work in our lab, and others, has shown that HRas trans-
formed cells including PH3MT, as well as N-Ras and
K-Ras transformed cells derived from the parental
MSU-1.1 cell strain, secrete significantly elevated levels
of both uPA and VEGF proteins compared to their non-
transformed parental cell strain ([18,19] and data not
shown). In the present study, our array analyses detected
>1.5 fold decrease in both VEGF and uPA gene expres-
sion when both Rac1 and Cdc42 were inhibited, suggest-
ing that Rac1 and/or Cdc42 play significant roles in uPA
and VEGF expression downstream of oncogenic HRas.
Rac1 and Cdc42 independently regulate secreted levels of
uPA protein in the context of activated HRas
T od e t e r m i n ew h e t h e rt h ed i f f e r e n c ei nuPA mRNA
levels corresponded to alterations in secreted levels of
uPA protein, ELISA analyses were conducted using tis-
sue culture supernatants (Fig. 5a). Inhibition of either
Rac1 or Cdc42 in PH3MT cells resulted in a 60% and
70% reduction in secreted uPA protein levels, respec-
tively. Interestingly, inhibition of both proteins resulted
in an additive reduction. Although our transcriptome
array analyses did not indicate whether or both Rac1
and/or Cdc42 affected uPA gene expression, this analy-
sis indicates that the activation of both proteins is
required for the full elaboration of increased uPA
secretion.
Figure 4 Transformed phenotypes elicited by expression of
Rac1
V12 or Cdc42
V12 in human fibroblasts. (a) MSU-1.1 fibroblasts
expressing either GFP alone (MSU-1.1-GFP-VC), or GFP-tagged
constitutively-activated proteins. (b) The indicated cell strains were
grown in medium with reduced serum (0.5% SCS). Growth curves
were plotted. Doubling time was calculated based on an equation
derived from a best-fit exponential curve when cells were in log-
phase growth. Error bars represent the SD of triplicate experiments.
(c) The indicated cell strains were plated in 0.33% agarose and
grown for three weeks. Each picture represents one representative
field from each cell line. This experiment was completed in
triplicate, each with similar results.
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expression of Rac1
V12 or Cdc42
V12 could increase the
levels of secreted uPA protein in the parental, non-
transformed MSU-1.1 cell strain (Fig. 5b). Interestingly,
expression of neither Cdc42
V12 nor Rac1
V12 resulted in
increased levels of secreted uPA protein, indicating that
although their activities are required to mediate the
secretion of uPA in Ras
V12-transformed PH3MT cells,
their activation alone is not sufficient to induce similar
increases in expression. In fact, activation of Rac1
resulted in a small, but reproducible decrease in levels
of secreted uPA protein.
Rac1 and Cdc42 independently regulate secreted levels of
VEGF protein
To determine if Rac1 and/or Cdc42 regulate HRas
V12-
induced VEGF secretion, we measured the amount of
VEGF protein secreted from PH3MT cell strains stably
expressing Rac1
N17 and/or Cdc42
N17 dominant-negative
mutants. Inhibition of Rac1 alone, or both Rac1 and
Cdc42, completely abrogated HRas
V12-induced secreted
VEGF levels (Fig. 6a). However, inhibition of Cdc42
alone resulted in only a 40% reduction. These data indi-
cate that in addition to Cdc42-mediated pathways, other
signalling networks, dependent on Rac1 activity, play
significant roles in VEGF secretion in the context of
HRas
V12 activation.
Current studies indicate that both Rac1 and Cdc42
regulate hypoxia inducible factor (HIF)-induced VEGF
expression in response to hypoxia in human hepatocel-
lular carcinoma and gastric cancer cell lines [20,21]. For
this reason, we hypothesized that both Rac1 and Cdc42
regulate secreted levels of VEGF protein from HRas
V12-
transformed fibroblasts grown in hypoxic conditions. To
a d d r e s st h i sh y p o t h e s i s ,w ecultured PH3MT derivative
cell strains expressing Rac1
N17 and/or Cdc42
N17 under
hypoxic (1% O2) conditions. Furthermore, we carried
Table 2 Summary of gene changes controlled by Rac1 and by Cdc42
Genes up-regulated
Name Fold Change Reference
Ubiquitin Conjugating enzyme 12 (UBC12) * 6.4 [39]
Elongation factor-1 alpha-2 * 2.3 [40]
Guanine nucleotide-binding regulatory protein (G-y-alpha) 2.2
mSin3A associated polypeptide p30 * 2.1 [41]
Rac protein kinase alpha 1.8
Coupling protein G(s) alpha-subunit (alpha-S1) 1.8
Histone H1x 1.8
80K-L protein * 1.6 [42]
Killer cell lectin-like receptor, Subfam. C, member 2 (NKG2C) * 1.6 [43]
Alpha subunit of GsGTP binding protein 1.5
Lipoprotein-associated coagulation inhibitor (LACI) 1.5
ATP synthase alpha subunit 1.3
Heat shock protein 70 (hsp70) * 1.3 [44]
Genes down-regulated
Name Fold Change
Insulin-like growth factor-binding protein-3 * -1.9 [45]
28s Ribosomal RNA gene -1.6
Cyclooxygenase-2 (hCox-2) * -1.6 [46]
Vascular endothelial growth factor (VEGF) * -1.6 [47]
Urokinase plasminogen activator (uPA) * -1.5 [48]
Human KIAA0628 -1.5
Asparagine synthetase -1.5
Axl tyrosine kinase receptor * -1.5 [49-51]
High mobility group isoform C (HMGI-C) * -1.5 [52-54]
Lnk adaptor protein -1.4
GTPase-activating protein ras p21 (RASA) -1.4
Human KIAA0728 protein -1.3
Axl tyrosine kinase receptor splice 2 * -1.3 [49-51]
N-myristoyltransferase 2 -1.3
Caveolin 2 * -1.3 [55]
Glycosylphosphatidylinositol-H (GPI-H) -1.3
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Page 10 of 15Figure 5 Activated Rac1 and Cdc42 independently regulate
uPA expression. The indicated cell strains were serum starved for
24 hours then stimulated with medium containing 10% SCS. (a)
Grown in the absence of tetracycline, PH3MT cell strains expressing
a vector control (PH3MT-VC-C2), Rac1
N17(PH3MT- Rac1
N17-C1),
Cdc42
N17 (PH3MT-Cdc42
N17-C2) or both Rac1
N17 and Cdc42
N17
(PH3MT-Rac1
N17/Cdc42
N17) were tested for uPA expression levels
using ELISA. Data is presented as percent of control. Error bars
indicate the SD from triplicate experiments. * indicates significant
difference, p < 0.05. ** indicates a significant difference compared
to PH3MT-Rac1
N17-C1 and PH3MT-Cdc42
N17-C2, p < 0.05. (b)
conditioned medium was collected from MSU-1.1 cells expressing
GFP alone (MSU-1.1-GFP-VC), GFP-tagged Rac1
V12 (MSU-1.1-GFP-
Rac1
V12) or GFP-tagged Cdc42
V12 (MSU-1.1-GFP-Cdc42
V12), and uPA
expression was analyzed. Data is presented as fold-induction of uPA
expression. Error bars represent the SD from triplicate experiments. *
indicates significant difference, p < 0.05.
Figure 6 Both Rac1 and Cdc42 regulate VEGF expression in
non-hypoxic and hypoxic conditions. All cell strains were serum
starved for 24 hours prior to exposure to the indicated agent.
Conditioned media were collected after 24 hr and ELISA analyses
were completed. The data is presented as either percent of control,
or fold induction as indicated in the figure. Error bars represent the
SD from triplicate experiments. (a) PH3MT cell strains expressing a
vector control (PH3MT-VC-C2), Rac1
N17 (PH3MT- Rac1
N17-C1),
Cdc42
N17 (PH3MT-Cdc42
N17-C2), or both (PH3MT-Rac1
N17/Cdc42
N17),
were stimulated with either medium containing 10% SCS, 100 μM
DFO, 100 μM CoCl2 or Hypoxia (1% O2). (b) MSU-1.1 cells expressing
GFP alone (MSU-1.1-GFP-VC-C2), or GFP-tagged Rac1
V12 (MSU-1.1-
GFP-Rac1
V12), or GFP-tagged Cdc42
V12 (MSU-1.1-GFP-Cdc42
V12). Cells
were stimulated with medium containing 10% SCS. * denotes a
significant difference (p < 0.01).
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chloride (CoCl2) or deferoxamine (DFO). Under each
condition, inhibition of either protein resulted in a 50%
- 60% reduction in the level of secreted VEGF protein,
whereas when these cells were exposed to either CoCl2
or DFO, inhibition of both Rac1 and Cdc42 completely
eliminated detectable levels of VEGF protein (Fig. 6a).
However, there was not an additive decrease in VEGF
secretion in cells exposed to hypoxia. Therefore, these
data indicate that both Rac1 and Cdc42 pathways are
required for VEGF expression in HRas
V12-transformed
human fibroblasts exposed to hypoxic conditions.
Because the activation of Rac1 and Cdc42 is required
for the full elaboration of VEGF expression downstream
of oncogenic HRas, we hypothesized that introduction
of Rac1
V12 or Cdc42
V12 protein in MSU-1.1 cells results
in an induction of VEGF protein secretion (Fig. 6b).
However, we found that expression of Rac1
V12 did not
induce VEGF expression in human fibroblasts. In con-
trast, expression of Cdc42
V12 induced a significant
increase in expression of VEGF (6-fold; p < 0.05). This
suggests that in human fibroblasts, Rac1 regulates the
levels of secreted VEGF in the context of HRas
V12-
induced mitogenic signalling, whereas the activation of
Cdc42 is sufficient to increase levels of secreted VEGF,
independent of other oncogenic HRas-mediated effector
pathways.
Discussion
In agreement with previous reports conducted in rodent
fibroblast cell lines, the data obtained in this study show
that both Rac1 and Cdc42 activity are essential for
maintaining HRas
V12-induced transformed phenotypes
of human fibroblasts [8,9,22]. In addition, we found that
activation of Rac1 in non-transformed human fibroblasts
results in their ability to grow in the absence of serum-
provided growth factors, and that activated Cdc42
potentiates anchorage independent growth. These data
corroborate the results of studies conducted with rodent
fibroblasts exhibiting these same properties, under iden-
tical physiological conditions, and with expression of
identical mutant proteins [8,10]. A known role for Rho
GTPase family members in general, and a specific role
for both Rac1 and Cdc42 in various mitotic processes is
but one possible way that inhibition of Rac1 and/or
Cdc42 may affect the transformed phenotypes measured
in this study [23]. In contrast to the results of rodent
studies, expression of activated mutants in human
MSU-1.1 cells failed to induce malignant transformation,
as defined by tumor growth. It is possible that the GFP
tag interferes with the function of these activated
mutants, or that levels of these proteins were insufficient
to fully transform the human cells. However, expression
of these mutants did result in the manifestation of
previously reported transformed properties. Therefore, it
is likely that malignant transformation of human fibro-
blasts requires the simultaneous dysregulation of a wide
array of independent signalling networks, in addition to
those mediated by Rac1 and Cdc42. In support of these
findings, recent reports indicate that modification of Ral
and caveolin-1-mediated pathways are required for
HRas
V12-induced malignant transformation of human
fibroblasts, but do not appear to be necessary for malig-
nant transformation of rodent fibroblasts [11,24,25].
Because Rac1 and Cdc42 are essential mediators of
HRas
V12-induced transformation, we carried out Affy-
metrix GeneChip analyses of HRas
V12-transformed cells
expressing tetracycline-regulated Rac1
N17 and Cdc42
N17
dominant-negative proteins. This allowed us to use the
same cell strain as the control and the experimental cell
populations. This analysis, allowed us to identify a
highly significant group of 29 genes whose level of
expression was significantly mediated by Rac1 and/or
Cdc42 activity, only 14 of which have previously been
reported to play a role in cancer.
It is likely that both Rac1 and Cdc42 mediate the
expression of downstream effectors by modulating both
post-transcriptional and transcriptional mechanisms. For
example, it is known that Ras regulates the activation of
JNK pathway mediators which, in some instances, affect
the stability of mRNA via A/U rich sequences in the
3’UTR of targeted gene products. Therefore, Rac1 and
Cdc42 may regulate both uPA and VEGF expression by
altering JNK activity, and thereby regulating uPA and
VEGF mRNA stability [26,27].
Transcriptional mechanisms also regulate expression
of the urokinase plasminogen activator (uPA) protein.
Cooperation of two PEA3/AP-1 binding sites in the uPA
promoter is required to mediate TPA-induced uPA
expression in NIH3T3 fibrobl a s t s[ 2 8 ] .F u r t h e r m o r e ,i t
has recently been shown that activation of the PI3K/Akt
pathway, known to be upstream of Rac1 and Cdc42
activity, positively correlates with uPA expression in an
ovarian cancer cell line [29]. Research from our labora-
tory has demonstrated that receptor bound uPA is pre-
sent at higher levels in fibroblasts capable of forming
fibrosarcomas including those transformed by N-, K-, or
HRas
V12 than it is in a number of normal, non-tumori-
genic human fibroblast cell strains [18]. The results of
our present study indicate that both Rac1 and Cdc42
regulate HRas
V12-induced uPA expression in parallel
pathways, perhaps through JNK and AP-1 regulation.
However, expression of activated Rac1 or Cdc42 did not
induce uPA protein expression in the parental MSU-1.1
human fibroblasts. This may be partially explained by
the results reported by Aguirre-Ghiso et al. [30] who
found that expression of dominant-negative RalA pro-
tein in v-Ras transformed NIH3T3 cells completely
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blocked tumor formation. Taken together, these results
strongly suggest that Ras-induced RalA, Rac1 and Cdc42
activities are all required to co-ordinately regulate
secreted levels of uPA protein in human fibroblasts, and
that expression of these proteins individually is not suf-
ficient to induce uPA expression.
VEGF is the best-studied mediator of angiogenesis
[31]. Our results show that in non-hypoxic conditions,
HRas
V12 induces VEGF expression in a Rac1-dependent
manner, whereas Cdc42 plays only a partial role. There-
fore, it is tempting to postulate that in this instance,
Cdc42 mediates one of multiple signalling pathways
downstream of Rac1, that when inactivated, partially dis-
rupts VEGF secretion. Ras-induced VEGF expression is
regulated by multiple mechanisms, including increased
transcription, translation and mRNA stabilization
[20,27,32-34]. For example, it has been shown that acti-
vation of ERK1/2, through the Raf-mediated Ras path-
way, increases the activity of HIF1 and Sp1 transcription
factors [20,33]. However, recent data from our labora-
tory indicate that reduction of Sp1 expression in
HRas
V12-transformed human fibroblasts does not affect
expression of VEGF [35]. Saniger et al. [34] recently
reported that activation of either Rac1 or Cdc42 can
induce transcription of VEGF through activation of JNK,
which results in increased transcription of the VEGF
gene product. Although multiple Rac1 and Cdc42 inde-
pendent pathways affecting HIF1 transcriptional net-
works exist [36], it is possible that in HRas
V12-
transformed human fibroblasts, Rac1 may play a partial
role in stabilizing HIF1 and/or activating JNK, which
then modulates secretion of VEGF protein.
Rac1 and Cdc42 have also been implicated in hypoxic-
induction of VEGF expression through regulation of p53
and VHL protein levels, as well as HIF1, and JNK acti-
vation [20,21,34]. In agreement with these studies, we
find that both Rac1 and Cdc42 play a role in hypoxia-
induced VEGF expression in HRas
V12-transformed fibro-
blasts. We also show that both Rac1 and Cdc42 mediate
VEGF expression under hypoxic conditions. However,
under the same conditions, inhibition of both Rac1 and
Cdc42 did not result in an additive suppression of
VEGF. In contrast, complete reduction in VEGF secre-
tion by these cells in the presence of hypoxia mimetics
DFO and CoCl2 was observed. This may result from
mechanistic differences in simulation of hypoxia using
mimetics compared to true hypoxic conditions, a result
that has been observed previously [20].
As noted above, In MSU-1.1 human cells, expression
of activated Cdc42, but not activated Rac1, results in
high levels of secreted VEGF protein. This indicates that
Cdc42 regulates the expression of VEGF in the absence
of other Ras-mediated effector pathways, whereas Rac1
does not. It has been shown that activation of Ost, the
RhoA- and Cdc42-specific GEF, can potently induce
JNK transcriptional pathways, and that Cdc42 can regu-
late EGFR signalling in an autocrine fashion, both
potentially impacting on the expression of VEGF
[37,38]. This may explain the ability of activated Cdc42,
but not Rac1 to induce VEGF secretion in the absence
of Ras activity.
Conclusions
Our research provides an incremental advancement of
what is currently known about the roles of Rac1 and
Cdc42 in Ras-induced transformation. We demonstrate
that although expression of constitutively-activated Rac1
and Cdc42 does not induce malignant-transformation of
human fibroblasts, both Rac1 and Cdc42 are essential
mediators of HRas
V12-induced transformation of such
cells. We also identify 29 Ras-induced Rac1- and Cdc42-
regulated genes. Furthermore, we validate the roles of
both Rac1 and Cdc42 in mediating the expression of
both uPA and VEGF protein. Finally, we identify a role
for both Rac1 and Cdc42 in the regulation of VEGF
protein expression in conditions of hypoxia.
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